OBJECTIVE
To determine if African-American men with newly diagnosed prostate cancer (PC) have higher pretreatment serum prostate-specific antigen (PSA) values after adjustment for clinical stage, age, and tumor grade, and to determine if any difference detected is related to tumor volume difference.
DESIGN
Consecutive case series of newly diagnosed PC patients between January 1990 and September 1994 and cohort analytic study of PC patients treated by radical prostatectomy (RP) and who had whole-mount pathologic tumor volume assessment between May 1993 December 1994.
SETTING
Tertiary care military medical center.
PATIENTS
A total of 541 evaluable newly diagnosed PC patients (408 white and 133 black) having pretreatment PSA assessment at one laboratory; 91 patients undergoing RP had whole-mount tumor volume analysis.
INTERVENTIONS
Medical record review for pretreatment PSA value, race, tumor grade, clinical stage, and age, as well as whole-mount pathologic assessment of RP specimen and measurement of tumor volume.
MAIN OUTCOME MEASURES
The PSA differences between black and white PC patients with adjustments for age, biopsy tumor grade (Gleason score), and clinical stage (TNM stage); PSA differences between black and white PC patients undergoing RP with adjustment for age, RP grade, clinical stage, and tumor volume.
RESULTS
The mean (geometric) PSA value for 133 black men was 14.00 ng/mL compared with 8.29 ng/mL for 408 white men (P < .001). The black patients had higher PSA values across all stage, grade, and age categories. The racial difference in PSA levels remained statistically significant when stage, grade, and age were simultaneously controlled for (P < .001). Multivariable odds ratio testing revealed that even after adjustment for stage, grade, and age, black patients were 2.2 times as likely as white patients to have a PSA value greater than 10.0 ng/mL (95% confidence interval, 1.3 to 3.6). Tumor volume (geometric mean) was 5.42 cm3 and 2.10 cm3 for black and white RP patients, respectively (P = .002). Across all clinical stages (T1a to T3), black men had tumor volumes 1.3 to 2.5 times greater than those of white men. Multivariable analysis of covariance revealed that tumor volume and stage of disease were important predictors of PSA level, but race, grade, and age were not. (The percentage of white and black patients whose cancer was detected by screening [75.4% vs 70.4%] or who had symptoms [37.7% vs 29.6%] was not significantly different.)
CONCLUSIONS
As a group, African-American men with newly diagnosed PC have higher PSA values at initial diagnosis than white men. This PSA difference appears to be due to larger tumor volumes within clinical (TNM) stage categories among black patients. Elevated PSA value was a surrogate for larger tumor volume in this cohort of black men. This stage-for-stage tumor volume disparity even in an equal-access health care environment should prompt further study of screening behavior and/or biological differences of PC in the black population.
[1]
R. Morton,et al.
Racial differences in adenocarcinoma of the prostate in North American men.
,
1994,
Urology.
[2]
I. Thompson,et al.
Military Rank as a Measure of Socioeconomic Status and Survival From Prostate Cancer
,
1994,
Southern medical journal.
[3]
J. Oesterling,et al.
The clinical usefulness of prostate specific antigen: update 1994.
,
1994,
The Journal of urology.
[4]
P. Scardino,et al.
The new american joint committee on cancer and international union against cancer tnm classification of prostate cancer
,
1994,
Cancer.
[5]
D. Bostwick,et al.
PSA-detected (clinical stage T1c or B0) prostate cancer. Pathologically significant tumors.
,
1993,
The Urologic clinics of North America.
[6]
Srinivasan Vijayakumar,et al.
Racial differences in prostate‐specific antigen levels in patients with local‐regional prostate cancer
,
1992,
The Prostate.
[7]
M. Pike,et al.
5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males
,
1992,
The Lancet.
[8]
K. Pienta,et al.
Effect of age and race on the survival of men with prostate cancer in the Metropolitan Detroit tricounty area, 1973 to 1987.
,
1995,
Urology.
[9]
Curtis Mettlin,et al.
Defining and updating the american cancer society guidelines for the cancer‐related checkup: Prostate and endometrial cancers
,
1993,
CA: a cancer journal for clinicians.
[10]
T. Tong,et al.
Cancer statistics, 1993
,
1993,
CA: a cancer journal for clinicians.